Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Conference Call
Company Participants:
Edward Berg – Senior Vice President and General Counsel
Steven Lo – Chief Executive Officer
James Cummings – Chief Medical Officer
Sean Tucker – Senior Vice President and Chief Scientific Officer
Phillip Lee – Chief Financial Officer
Conference Call Participants:
Cheng Li – Oppenheimer
Mayank Mamtani – B. Riley Securities
Liang Cheng – Jefferies
Operator:
Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call.
Vaxart, Inc. recently held its Q3 2024 Earnings Conference Call on November 13, 2024, to discuss their financial performance and provide a business update. The conference call featured key company executives including Senior Vice President and General Counsel, Edward Berg; Chief Executive Officer, Steven Lo; Chief Medical Officer, James Cummings; Senior Vice President and Chief Scientific Officer, Sean Tucker; and Chief Financial Officer, Phillip Lee.
Effects on Me:
As a shareholder or potential investor in Vaxart, Inc., the information shared during the conference call can have a direct impact on your investment decisions. Understanding the company’s financial results and future outlook is crucial in assessing the potential growth and profitability of your investment in Vaxart.
Effects on the World:
For the world, Vaxart’s financial performance and business update can have broader implications on the healthcare industry and public health. Vaxart is a biotechnology company focused on the development of oral vaccines, which could revolutionize the way vaccines are administered and improve global vaccination efforts.
Conclusion:
The Q3 2024 Earnings Conference Call by Vaxart, Inc. provided valuable insights into the company’s financial performance and strategic direction. Investors and stakeholders can use this information to make informed decisions, while the innovative work of Vaxart has the potential to positively impact the world of healthcare and vaccination.
